Lundbeck reads last rites on another failed PhIII Alzheimer’s program
Lundbeck and Otsuka have racked up two more Phase III flops for their 5-HT6 antagonist idalopirdine, setting up corporate last rites for yet another failed Alzheimer’s drug.
The Danish biotech said in their Q4 roundup today that “the efficacy profile with idalopirdine observed in these studies and in the (first) STARSHINE study do not demonstrate efficacy to support a regulatory submission.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.